|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Whereas, CM3D was characterised by a prevailing expression of anti-inflammatory cytokines such as IL-10 and LIF, along with trophic factors involved in different mechanisms leading to tissue regeneration, such as PDGF-BB, FGF-2, I-309, SCF, and GM-CSF; CM2D presented relatively higher levels of IL-6, MCP-1, and IL-21, with recognised pro-inflammatory roles in joint disease and pleiotropic effects in the progression of rheumatoid arthritis (RA).
|
30804924 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously proposed the hypothesis that the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA) based on our observations that it is the dominant inducer of interleukin-1 (IL-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in RA synovial joint mononuclear (MNC) cells in culture.
|
1320571 |
1992 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have reported previously that metastatic lymph node 51 (MLN51) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are involved in the proliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis.
|
18513326 |
2008 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using neutralizing antibodies to tumor necrosis factor (TNF)-alpha we demonstrated that GM-CSF production in RA synovial cell cultures is dependent on the continued presence of active TNF-alpha.
|
1915559 |
1991 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the molecular basis for the MTX anti-inflammatory action, we explored toll-like receptor (TLR), RA synovial fluid (RASF) and tumour necrosis factor receptor (TNFR)-initiated signalling in MTX-exposed GM-CSF-primed macrophages.
|
29431121 |
2018 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF and granulocyte macrophage-colony stimulating factor (GM-CSF) have proinflammatory activity and both contribute, for example, to rheumatoid arthritis pathogenesis.
|
29563337 |
2018 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study therefore identifies convergent MAPK pathways on Ser345 that are involved in GM-CSF- and TNF-alpha-induced priming of neutrophils and are activated in RA.
|
16778989 |
2006 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This 24-week, phase IIb, double-blind study was undertaken to evaluate the efficacy and safety of mavrilimumab (a monoclonal antibody to granulocyte-macrophage colony-stimulating factor receptor α) and golimumab (a monoclonal antibody to tumor necrosis factor [anti-TNF]) in patients with rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs) (referred to as DMARD-IR) and/or inadequate response to other anti-TNF agents (referred to as anti-TNF-IR).
|
28941039 |
2018 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The TTP pathway of TNF-alpha and GM-CSF mRNA degradation is a possible novel target for anti-TNF-alpha therapies for rheumatoid arthritis, and also for other conditions proven to respond to anti-TNF-alpha therapy.
|
15535838 |
2004 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings demonstrate that IL-17 regulates SHP-2 expression and IL-17RA/STAT-3 dependent production of Cyr61, IL-23, GM-CSF and RANKL in AA-FLS and may reveal a new insight into the pathogenesis of RA.
|
28898718 |
2017 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silencing of NFkappaB1 by small interfering RNA abrogated the capacity of RA bone marrow CD34+ cells to differentiate into fibroblast-like cells and to produce MMP-1 and vascular endothelial growth factor upon stimulation with stem cell factor, granulocyte-macrophage colony stimulating factor and TNF-alpha without influencing their viability and capacity to produce beta2-microglobulin.
|
16519794 |
2006 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several in vitro and in vivo studies showed that granulocyte-macrophage colony-stimulating factor (GM-CSF), known to be a hematopoietic factor, is also one of the proinflammatory cytokines involved in macrophage activation, crucial for the pathogenic network of RA.
|
28144129 |
2017 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis.
|
17062647 |
2007 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
RA (n = 7) and healthy control (n = 7) neutrophils were treated with baricitinib or tofacitinib for 30 min, prior to incubation in the absence or presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) or interferon (IFN)-γ. JAKi prevented GM-CSF- and IFN-γ-induced apoptosis delay in RA and healthy control neutrophils in a dose-dependent manner.
|
28369741 |
2017 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Polymorphisms in several genes were associated with IL-6 levels (including IL10, TYK2, and CD40L in SLE and DRB1, NOD2, and CSF1 in RA) or with TNFα levels (including TNFSF4 and CSF2 in SLE and PTPN2, DRB1, and NOD2 in RA).
|
25652333 |
2015 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
|
30358109 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
mRNAs encoding RANKL, RANK, OPG and macrophage-colony stimulating factor were expressed by cells isolated from RA joints.
|
11426018 |
2001 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, this combination suppressed more IFN-γ secretion and NFAT-regulated gene (GM-CSF and IFN-γ) expression in RA-MNCs than normal MNCs via decreasing the activity of NFATc1.
|
22385242 |
2012 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.
|
22446963 |
2012 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
|
21613310 |
2011 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, was evaluated in patients with moderate-to-severe RA.
|
28213566 |
2017 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interleukin 1-beta (IL-1 beta), IL-2, IL-4, IL-5, IL-6, IL-8, tumour necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta) and granulocyte-macrophage colony-stimulating factor (GM-CSF) gene expression was determined in knee synovium of 16 patients with rheumatoid arthritis (RA) and 16 patients with seronegative spondyloarthropathies (SSP), by using polymerase chain reaction (PCR) amplification.
|
9117172 |
1997 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis.
|
16859503 |
2006 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, synovial fibroblasts of a patient from rheumatoid arthritis (RA) were transformed with LT gene to analyze the effect of SV40-mediated transformation on the production of cytokines, such as IL-6, IL-8, and GM-CSF, that are under the control of interleukin-1 beta (IL-1 beta), a physiological inducer of nuclear factor kappa B (NF-kappa B).
|
10470256 |
1999 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In RA, plasma S100A4 correlated with increased CSF2, and increased PRDM8 transcription in RA monocytes was associated with increased plasma CCL5 and IL-6, as well as therapy-resistance.
|
31037071 |
2019 |